Globus Medical (NYSE:GMED) announced today that it agreed to acquire chronic pain treatment developer Nevro (NYSE:NVRO).

GlobalData senior medical device analyst says the acquisition could see Nevro’s growth outside the US accelerate.

Nevro Corp is a medical device company. Its key product is the HFX spinal cord stimulation (SCS) platform, which includes the Senza SCS system, an evidence-based neuromodulation system for the ...

Nevro’s comprehensive HFX™ spinal cord stimulation (SCS) platform includes the Senza® SCS system and support services for the treatment of chronic pain of the trunk and limb and painful diabetic ...

Analysts said Nevro’s valuation was “inexpensive,” but the spinal cord stimulation business can benefit from Globus’ scale ...

Globus Medical’s world is about to get a little bigger, as the orthopedic devicemaker moves to acquire Nevro and its neuromodulation platforms for treating chronic pain. The all-cash deal comes ...

Nevro (NYSE:NVRO – Get Free Report) was upgraded by research analysts at Jefferies Financial Group from an “underperform” rating to a “hold” rating in a research note issued to investors on Monday, ...